Literature DB >> 28609660

SnapShot: Immune Checkpoint Inhibitors.

Gabriel Abril-Rodriguez1, Antoni Ribas2.   

Abstract

Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance). A better understanding of the molecular mechanisms underlying checkpoint blockade therapies will facilitate the design of novel strategies to treat and prevent resistance. To view this SnapShot, open or download the PDF.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28609660     DOI： 10.1016/j.ccell.2017.05.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  70 in total

1.  Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.

Authors:  Nishant Mohan; Jiangsong Jiang; Milos Dokmanovic; Wen Jin Wu
Journal:  Antib Ther       Date:  2018-08-31

Review 2.  Checkpoint Inhibitors: Applications for Autoimmunity.

Authors:  Anna S Tocheva; Adam Mor
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

Review 3.  Mechanisms of Resistance to PD-1 and PD-L1 Blockade.

Authors:  Theodore S Nowicki; Siwen Hu-Lieskovan; Antoni Ribas
Journal:  Cancer J       Date:  2018 Jan/Feb       Impact factor: 3.360

Review 4.  Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer.

Authors:  Xianda Zhao; Audre May; Emil Lou; Subbaya Subramanian
Journal:  Transl Res       Date:  2018-02-12       Impact factor: 7.012

5.  Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models.

Authors:  Qiaohong Wang; Jingze Gao; Wen Di; Xia Wu
Journal:  Cancer Immunol Immunother       Date:  2020-04-28       Impact factor: 6.968

6.  T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.

Authors:  Natalie J Neubert; Martina Schmittnaegel; Natacha Bordry; Sina Nassiri; Noémie Wald; Christophe Martignier; Laure Tillé; Krisztian Homicsko; William Damsky; Hélène Maby-El Hajjami; Irina Klaman; Esther Danenberg; Kalliopi Ioannidou; Lana Kandalaft; George Coukos; Sabine Hoves; Carola H Ries; Silvia A Fuertes Marraco; Periklis G Foukas; Michele De Palma; Daniel E Speiser
Journal:  Sci Transl Med       Date:  2018-04-11       Impact factor: 17.956

Review 7.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 8.  Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.

Authors:  R Zou; Y Wang; S Cui; F Ye; X Zhang; M Wang
Journal:  Clin Transl Oncol       Date:  2021-05-17       Impact factor: 3.405

9.  Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma.

Authors:  Jingjing Guo; Saixia Wang; Yujing Han; Zhongyuan Jia; Runchao Wang
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

10.  A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.

Authors:  Xiaohan Zhou; Jun Du; Chengdong Liu; Hanyi Zeng; Yuting Chen; Li Liu; Dehua Wu
Journal:  Front Immunol       Date:  2021-07-09       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.